Fermer le menu


Orphanse Healthcare focuses on the development of alternatives pharmaceutical solutions.

Orphanse Healthcare combines several innovative factors:

• An original way of administration (oromucosal route)

• A new patented pharmaceutical formulation

• A simple and economic delivery device

Orphanse Heathcare obtained its clinical trial authorization in May 2018 by the french regulatory authority (ANSM) and the clinical part of the first pilot trial has been achieved in August 2018.

The next pilot study will start in Q1/2019.


Strategic application domain: Human Medicine

Application market: Neurology & Mental Health Disorders, Others

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Drug delivery device & Technologies, Others

Created on april 15th, 2015 - 3 employees



60 avenue Rockfeller 69008 Lyon



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.